A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Trial ID or NCT#

NCT00250432,

Status

not recruiting iconNOT RECRUITING

Purpose

Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)

Official Title

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Clinical and Laboratory evidence of blood stream &/or systemic candida infections
Exclusion Criteria:
  1. - Possible candida contamination - Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections - Acute or moderately severe liver disease - Abnormal liver function tests - Abnormal blood clotting for patients on blood thinners

Investigator(s)

Wes (Janice) Brown
Wes (Janice) Brown
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Infectious disease doctor
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Dora Ho
Dora Ho
Infectious disease doctor
Clinical Professor, Medicine - Infectious Diseases

Contact us to find out if this trial is right for you.

Contact

Joanna Schaenman